Stableford Capital II LLC Acquires 1,642 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Stableford Capital II LLC significantly increased its holdings in Thermo Fisher Scientific, acquiring an additional 1,642 shares and raising its position by 147.3% in the second quarter, bringing its total to 2,757 shares worth approximately $1.1 million.
• Analysts are mixed on Thermo Fisher's stock with a consensus rating of "Moderate Buy" and an average price target of $589.10, while several firms have recently revised their price objectives and ratings.
• Insider trading activity includes significant share sales by executives, with insiders collectively selling 30,066 shares valued at $14.2 million, highlighting possible shifts in investor confidence.

Stableford Capital II LLC raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 147.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,757 shares of the medical research company's stock after purchasing an additional 1,642 shares during the quarter. Stableford Capital II LLC's holdings in Thermo Fisher Scientific were worth $1,118,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in TMO. Mondrian Investment Partners LTD grew its position in Thermo Fisher Scientific by 146.1% in the first quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock worth $106,738,000 after acquiring an additional 127,357 shares in the last quarter. Caledonia Investments PLC boosted its holdings in shares of Thermo Fisher Scientific by 11.5% in the 2nd quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company's stock worth $45,299,000 after purchasing an additional 11,500 shares during the period. Foresight Group Ltd Liability Partnership increased its position in shares of Thermo Fisher Scientific by 3,242.7% during the 1st quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company's stock valued at $29,113,000 after purchasing an additional 56,747 shares during the last quarter. Advisors Capital Management LLC raised its holdings in Thermo Fisher Scientific by 6.7% during the 1st quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company's stock valued at $63,201,000 after buying an additional 7,967 shares during the period. Finally, New England Research & Management Inc. lifted its position in Thermo Fisher Scientific by 28.6% in the second quarter. New England Research & Management Inc. now owns 2,548 shares of the medical research company's stock worth $1,033,000 after buying an additional 567 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on TMO shares. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday. Evercore ISI raised their price objective on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 7th. UBS Group upped their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Hsbc Global Res lowered Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Finally, JPMorgan Chase & Co. upped their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an "overweight" rating in a research report on Thursday, October 9th. Fifteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $589.10.

Thermo Fisher Scientific Stock Up 0.3%

Shares of NYSE TMO opened at $527.34 on Thursday. The stock has a 50 day moving average price of $492.55 and a 200 day moving average price of $448.75. The firm has a market capitalization of $199.13 billion, a price-to-earnings ratio of 30.50, a PEG ratio of 2.85 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period in the previous year, the company posted $5.37 EPS. Thermo Fisher Scientific's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,066 shares of company stock valued at $14,182,963. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.